Vaccination is one of the cornerstones in the efforts towards ending the coronavirus disease 2019 (COVID-19) pandemic. However, several adverse effects of COVID-19 vaccination have been identified. Pityriasis rosea (PR)-like eruption is a rare cutaneous complication of immunization. To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. Treatment with topical 0.1% triamcinolone acetonide twice per day showed partial response after seven days. Despite this rare complication, our report highlights that the presence of PR-like eruption is not a contraindication for subsequent vaccinations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452904 | PMC |
| http://dx.doi.org/10.3389/fmed.2021.752443 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pityriasis following COVID-19 vaccinations: a systematic review.
Dermatol Reports
March 2024
Plastic Surgery Vegas, Las Vegas, NV, USA.
Article Synopsis
- A systematic review was conducted to investigate cutaneous reactions, specifically pityriasis eruptions, after COVID-19 vaccinations, revealing 47 case reports involving 94 patients.
- The findings showed that 64.9% had pityriasis rosea as the most common reaction, with Pfizer-BioNTech being the most reported vaccine associated with these skin reactions.
- The study highlighted a significant discrepancy in post-vaccination pityriasis reactions between Pfizer and Moderna vaccines, suggesting the need for further research to understand these differences better.
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review.
Clin Cosmet Investig Dermatol
January 2024
Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
COVID-19 pandemic completely changed every aspect of human life. Several measures were adopted to limit the spreading of the infection. Among these, vaccination was the main one.
View Article and Find Full Text PDFPityriasis Rosea Following Pfizer-BioNTech Vaccination in an Adolescent Girl.
Cureus
July 2022
Department of Dermatology, Imam Abdulrahman bin Faisal University, Al Khobar, SAU.
Article Synopsis
- Pityriasis rosea (PR) is a temporary skin disorder starting with a single patch (herald patch) and followed by more lesions within 1-2 weeks.
- A case was reported involving a 15-year-old girl who developed PR symptoms after her second Pfizer-BioNTech COVID-19 vaccine dose, including a primary patch on her wrist and itchy skin eruptions.
- The patient was treated successfully with acyclovir, and the report suggests further research is needed to explore the link between COVID-19 vaccination and the occurrence of PR or similar skin reactions.
Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature.
JAAD Int
June 2022
Department of Dermatology, The University of Texas Health Science Center, Houston, Texas.
A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.
View Article and Find Full Text PDFPityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination.
Clin Dermatol
December 2022
Dermatology Unit, Ospedale Policlinico San Martino, Genoa, Italy. Electronic address:
Pityriasis rosea (PR), PR-like eruptions (PR-LE), and herpes zoster have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination. PR is a self-limiting exanthematous disease and herpes zoster is a treatable condition; therefore, their occurrence does not require discontinuation of the vaccination schedule. PR-LE is a hypersensitivity reaction and is, therefore, less predictable in its course.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!